News

The expanded indication is approved to reduce excess body weight and maintain reduction long-term in children 2 years and up with obesity due to BBS, POMC, or LEPR deficiency.

"Tapinarof comes in with that mixture of the short-term studies and longer-term studies intermittently, giving us a nice, effective alternative non-steroid for eczema across the ages."

The primary endpoint was non-inferiority in HbA1c levels after 26 weeks.

Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, highlights the latest issue of Contemporary Pediatrics.

"Our findings support the recommendation of a healthy diet based on the current guidelines (as measured by the HEI) during pregnancy, since it may reduce patterns of infant growth outside reference ranges."

Nathan Kuppermann, MD, MPH, explains the different quartiles of the pediatric emergency department readiness scale, and why the top tier is so crucial for pediatric patients.

With the federal agency's decision, remestemcel-L-rknd has become the first FDA-approved mesenchymal stromal cell therapy.

This week, our experts weigh in on treatments not specifically indicated for COVID-19 treatment, including metformin, and concerns around using medications in this way.

Can you diagnose this healthy, 8.2-lb girl with lesions primarily on her lower lip but also her upper lip, cheeks, and nasolabial folds?

From new topical dermatology treatments for atopic dermatitis to the first nasal spray to treat type 1 allergic reactions, these are our top FDA approvals of 2024.

Currently, golimumab is approved in adults with moderately to severely active ulcerative colitis.

Greg Forlenza, MD, offers practical advise for primary care providers regarding continuous glucose monitors and automatic insulin delivery systems.

The federal agency has set a target action date of June 10, 2025 for potential approval.

According to Galderma, approval is based on positive results from the phase 3 ARCADIA clinical trial program.

"I really hope this becomes a first-line agent that people are comfortable prescribing whether they are in dermatology, pediatric dermatology, or primary care."

A discussion of the evolving landscape of diabetes technology and its implications for primary care providers.

The halt follows a severe respiratory disease safety signal observed in a July 2024 phase 1 trial of Moderna's mRNA-1345 and mRNA-1365 vaccine candidates.

In this episode, the panel discusses therapies and care around inpatients including mechanical ventilation, extracorporeal membrane oxygenation (ECMO), and remdesivir.

Pharming Group N.V. plans to include these findings in worldwide regulatory filings in 2025.

A good correlation and statistical agreement with total serum bilirubin was observed in a study of a new smartphone-based machine learning app, leaving it a potential neonatal jaundice screening tool.

In the study through 76 weeks, no new risks were observed with once-daily upadacitinib (15 mg or 30 mg).

The submission to treat PsO is for children aged 6 years and up while the jPsA submission is to treat children aged 5 years and older.

Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the final Contemporary Pediatrics journal of the year.

Zelicapavir demonstrated a favorable safety profile and was well-tolerated. The N-protein inhibitor has been granted Fast Track Designation by the FDA.

Respondents reported decreased diarrhea severity, improved patient quality of life, and decreased treatment discontinuation among patients with Rett syndrome treated with trofinetide.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Results demonstrated that those with earlier asthma onset had slower development of episodic memory.

A new study highlights how depression may drive dysmenorrhea through shared genetic pathways, emphasizing the need for mental health screening and holistic care for women.

In our latest roundtable series, we cover different therapies around COVID-19 treatment and prevention.

Both monthly migraine days and headache days were reduced vs placebo in patients aged 6 to 17 years.